In order to more accurately and objectively evaluate the efficacy and safety of RET-TKIs in the treatment of RET fusion-positive NSCLC, our study combined the results of several studies to provide objective evidence of the efficacy and safety of RET-TKIs in the treatment of RET fusion-positive NSCLC. The gene discussed is RET; the disease is non-small cell lung carcinoma.